# Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults

> **NCT03783130** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 16 (actual)

## Conditions studied

- Human Immunodeficiency Virus Prevention
- Human Immunodeficiency Virus (HIV)

## Interventions

- **BIOLOGICAL:** VRC-HIVRGP096-00-VP
- **OTHER:** Alum Adjuvant

## Key facts

- **NCT ID:** NCT03783130
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-07
- **Primary completion:** 2020-06-24
- **Final completion:** 2020-06-24
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2021-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03783130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03783130, "Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults". Retrieved via MORVS 2026-10-15 from https://api.morvs.ai/clinical/NCT03783130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*